



## INTERIM REPORT

12-week period ended December 17, 2022

1<sup>st</sup> Quarter 2023

---

### HIGHLIGHTS

#### 2023 FIRST QUARTER

- Sales of \$4,670.9 million, up 8.2%
  - Food same-store sales<sup>(1)</sup> up 7.5%
  - Pharmacy same-store sales<sup>(1)</sup> up 7.7%
  - Net earnings of \$231.1 million, up 11.3%, and adjusted net earnings<sup>(1)</sup> of \$237.6 million, up 10.9%
  - Fully diluted net earnings per share of \$0.97, up 14.1%, and adjusted fully diluted net earnings per share<sup>(1)</sup> of \$1.00, up 13.6%
  - Declared dividend of \$0.3025 per share, up 10.0% versus last year
-



## REPORT TO SHAREHOLDERS

Dear Shareholders,

I am pleased to present our interim report for the first quarter of Fiscal 2023 ended December 17, 2022.

Sales in the first quarter of Fiscal 2023 remained strong, reaching \$4,670.9 million, up 8.2% from the first quarter of 2022 mainly due to higher inflation this quarter. Food same-store sales were up 7.5% versus the same quarter last year (down 1.4% in the first quarter of 2022). Online food sales<sup>(1)</sup> were up 40.0% versus last year (flat in 2022). Our food basket inflation was 10.0%, the same level as the previous quarter. Pharmacy same-store sales were up 7.7% (7.7% in the first quarter of 2022), with a 6.5% increase in prescription drugs<sup>(1)</sup> and a 10.2% increase in front-store sales<sup>(1)</sup>, primarily driven by over-the-counter products, cosmetics and health and beauty.

First quarter net earnings were \$231.1 million in Fiscal 2023 compared with \$207.7 million in 2022 and fully diluted net earnings per share were \$0.97 compared with \$0.85 in 2022, up 11.3% and 14.1% respectively. Taking into account adjustment for the 2023 and 2022 first quarters, the after-tax amortization of intangible assets acquired in connection with the Jean Coutu Group acquisition, adjusted net earnings<sup>(1)</sup> for the first quarter of Fiscal 2023 totalled \$237.6 million compared with \$214.2 million for the corresponding quarter of 2022 and adjusted fully diluted net earnings per share<sup>(1)</sup> amounted to \$1.00 versus \$0.88, up 10.9% and 13.6% respectively.

On January 23, 2023, the Board of Directors declared a quarterly dividend of \$0.3025 per share, an increase of 10.0% versus last year quarterly dividend.

We delivered solid results in the first quarter, gaining market share in a very competitive environment. As inflationary pressures persist, our teams did an excellent job to offer the best value possible to customers in our stores, pharmacies and online and I thank them for their hard work. We will continue<sup>(2)</sup> to execute on our business plans to deliver a strong value proposition to our customers, invest in our retail network and infrastructure, and support our communities. As the Company proudly celebrates its 75<sup>th</sup> anniversary, we look forward to continued growth<sup>(2)</sup> and success for all stakeholders.

Eric La Flèche  
President and Chief Executive Officer

January 24, 2023

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



## MANAGEMENT'S DISCUSSION AND ANALYSIS

The following Management's Discussion and Analysis (MD&A) sets out the financial position and consolidated results of METRO INC. on December 17, 2022 and for the 12-week period then ended. It should be read in conjunction with the unaudited interim condensed consolidated financial statements and accompanying notes in this interim report.

The unaudited interim condensed consolidated financial statements for the 12-week period ended December 17, 2022 have been prepared by management in accordance with IAS 34 *Interim Financial Reporting*. They should be read in conjunction with the audited annual consolidated financial statements and accompanying notes and the MD&A presented in the Corporation's 2022 Annual Report. Unless otherwise stated, the interim report is based on information as at January 13, 2023.

Additional information, including the Certification of Interim Filings for the quarter ended December 17, 2022 signed by the President and Chief Executive Officer and the Executive Vice-President, Chief Financial Officer and Treasurer, will also be available on the SEDAR website at: [www.sedar.com](http://www.sedar.com).

## OPERATING RESULTS

### SALES

Sales in the first quarter of Fiscal 2023 remained strong, reaching \$4,670.9 million, up 8.2% from the first quarter of 2022 mainly due to higher inflation this quarter. Food same-store sales were up 7.5% versus the same quarter last year (down 1.4% in the first quarter of 2022). Online food sales<sup>(1)</sup> were up 40.0% versus last year (flat in 2022). Our food basket inflation was 10.0%, the same level as the previous quarter. Pharmacy same-store sales were up 7.7% (7.7% in the first quarter of 2022), with a 6.5% increase in prescription drugs<sup>(1)</sup> and a 10.2% increase in front-store sales<sup>(1)</sup>, primarily driven by over-the-counter products, cosmetics and health and beauty.

### OPERATING INCOME BEFORE DEPRECIATION AND AMORTIZATION

This earnings measurement excludes financial costs, taxes, depreciation and amortization.

Operating income before depreciation and amortization for the first quarter of Fiscal 2023 totalled \$462.0 million, or 9.9% of sales, an increase of 8.9% versus the corresponding quarter of Fiscal 2022.

Gross margin<sup>(1)</sup> for the first quarter of Fiscal 2023 was 19.6% versus 19.9% for the corresponding period of 2022, resulting mainly from higher cost of goods sold in food.

Operating expenses as a percentage of sales for the first quarter of Fiscal 2023 were 9.8% versus 10.2% in the corresponding quarter of 2022. The decrease in the percentage of operating expenses on sales is mainly due to good cost control and good leverage on the high level of sales.

### DEPRECIATION AND AMORTIZATION

Total depreciation and amortization expense for the first quarter of Fiscal 2023 was \$120.1 million versus \$112.5 million for the corresponding quarter of 2022. This increase reflects the additional investments in supply chain and logistics as well as in-store technology.

### NET FINANCIAL COSTS

Net financial costs for the first quarter of Fiscal 2023 were \$27.1 million compared with \$28.7 million for the corresponding quarter of 2022. This reduction is mainly due to the decrease in interest on pension assets and liabilities as well as higher capitalized interest.

### INCOME TAXES

The income tax expense of \$83.7 million for the first quarter of Fiscal 2023 represented an effective tax rate of 26.6% compared with an income tax expense of \$75.2 million and an effective tax rate of 26.6% in the first quarter of Fiscal 2022.

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



## NET EARNINGS AND ADJUSTED NET EARNINGS<sup>(1)</sup>

Net earnings for the first quarter of Fiscal 2023 were \$231.1 million compared with \$207.7 million for the corresponding quarter of 2022, while fully diluted net earnings per share were \$0.97 compared with \$0.85 in 2022, up 11.3% and 14.1% respectively. Excluding the specific item shown in the table below, adjusted net earnings<sup>(1)</sup> for the first quarter of Fiscal 2023 totalled \$237.6 million compared with \$214.2 million for the corresponding quarter of 2022 and adjusted fully diluted net earnings per share<sup>(1)</sup> were to \$1.00 versus \$0.88, up 10.9% and 13.6% respectively.

### Net earnings and fully diluted net earnings per share (EPS) adjustments<sup>(1)</sup>

	12 weeks / Fiscal Year					
	2023		2022		Change (%)	
	Net earnings (Millions of dollars)	Fully diluted EPS (Dollars)	Net earnings (Millions of dollars)	Fully diluted EPS (Dollars)	Net earnings	Fully diluted EPS
Per financial statements	231.1	0.97	207.7	0.85	11.3	14.1
Amortization of intangible assets acquired in connection with the Jean Coutu Group acquisition, net of taxes of \$2.4	6.5		6.5			
Adjusted measures <sup>(1)</sup>	237.6	1.00	214.2	0.88	10.9	13.6

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



## QUARTERLY HIGHLIGHTS

<i>(Millions of dollars, unless otherwise indicated)</i>	2023	2022	2021	Change (%)
<b>Sales</b>				
Q1 <sup>(3)</sup>	<b>4,670.9</b>	4,316.6	—	8.2
Q4 <sup>(3)</sup>	—	4,432.6	4,092.0	8.3
Q3 <sup>(4)</sup>	—	5,865.5	5,719.8	2.5
Q2 <sup>(3)</sup>	—	4,274.2	4,193.0	1.9
<b>Net earnings</b>				
Q1 <sup>(3)</sup>	<b>231.1</b>	207.7	—	11.3
Q4 <sup>(3)</sup>	—	168.7	194.0	(13.0)
Q3 <sup>(4)</sup>	—	275.0	252.4	9.0
Q2 <sup>(3)</sup>	—	198.1	188.1	5.3
<b>Adjusted net earnings<sup>(1)</sup></b>				
Q1 <sup>(3)</sup>	<b>237.6</b>	214.2	—	10.9
Q4 <sup>(3)</sup>	—	219.4	200.6	9.4
Q3 <sup>(4)</sup>	—	283.8	261.2	8.7
Q2 <sup>(3)</sup>	—	204.7	194.7	5.1
<b>Fully diluted net earnings per share (Dollars)</b>				
Q1 <sup>(3)</sup>	<b>0.97</b>	0.85	—	14.1
Q4 <sup>(3)</sup>	—	0.70	0.79	(11.4)
Q3 <sup>(4)</sup>	—	1.14	1.03	10.7
Q2 <sup>(3)</sup>	—	0.82	0.75	9.3
<b>Adjusted fully diluted net earnings per share<sup>(1)</sup> (Dollars)</b>				
Q1 <sup>(3)</sup>	<b>1.00</b>	0.88	—	13.6
Q4 <sup>(3)</sup>	—	0.92	0.81	13.6
Q3 <sup>(4)</sup>	—	1.18	1.06	11.3
Q2 <sup>(3)</sup>	—	0.84	0.78	7.7

<sup>(3)</sup> 12 weeks

<sup>(4)</sup> 16 weeks

Sales in the first quarter of Fiscal 2023 remained strong, reaching \$4,670.9 million, up 8.2% from the first quarter of 2022 mainly due to higher inflation this quarter. Food same-store sales were up 7.5% versus the same quarter last year (down 1.4% in the first quarter of 2022). Online food sales<sup>(1)</sup> were up 40.0% versus last year (flat in 2022). Our food basket inflation was 10.0%, the same level as the previous quarter. Pharmacy same-store sales were up 7.7% (7.7% in the first quarter of 2022), with a 6.5% increase in prescription drugs<sup>(1)</sup> and a 10.2% increase in front-store sales<sup>(1)</sup>, primarily driven by over-the-counter products, cosmetics and health and beauty.

Sales in the fourth quarter of Fiscal 2022 remained strong, reaching \$4,432.6 million, up 8.3% from the fourth quarter of 2021 mainly due to higher inflation this quarter. Food same-store sales were up 8.0% (down 2.9% in 2021) versus the same quarter last year. Online food sales were up 33.0% versus last year (flat in 2021). Our food basket inflation increased to 10.0% from 8.5% in the previous quarter. Pharmacy same-store sales were up 7.4% (4.1% in 2021), with a 6.4% increase in prescription drugs supported by COVID-related activities such as the distribution of rapid tests and a 9.9% increase in front-store sales, primarily driven by over-the-counter products and cosmetics.

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



Sales in the third quarter of Fiscal 2022 remained strong, reaching \$5,865.5 million, up 2.5% versus elevated sales in the third quarter of 2021 due to the pandemic. Food same-store sales were up 1.1% (down 3.6% in 2021) versus the same quarter last year. Online food sales were flat versus last year (up 19.0% in 2021). Our food basket inflation was about 8.5% (5.0% in the previous quarter). Pharmacy same-store sales were up 7.2% (7.6% in 2021), with a 5.6% increase in prescription drugs supported by COVID-related activities such as the distribution of rapid tests and a 10.7% increase in front-store sales, primarily driven by over-the-counter products and cosmetics.

Sales in the second quarter of Fiscal 2022 remained strong, reaching \$4,274.2 million, up 1.9% compared to \$4,193.0 million in the second quarter of 2021. Food same-store sales were up 0.8% versus the same quarter last year and were up 11.5% for the first 8 weeks of the second quarter compared to the same period of 2020 (pre-COVID period). Online food sales increased by 6.0% versus last year (up 240.0% in 2021). Our food basket inflation was slightly below 5.0% (3.5% in the previous quarter). Pharmacy same-store sales were up 9.4%, with a 7.7% increase in prescription drugs supported by COVID-related activities such as the distribution of rapid tests, and a 13.3% increase in front-store sales supported by a stronger cough and cold season as well as the lower sales last year because of the six-week ban of the sale of non-essential products. Pharmacy same-store sales were up 11.0% for the first 8 weeks of the second quarter versus 2020 (pre-COVID period).

Net earnings for the first quarter of Fiscal 2023 were \$231.1 million compared with \$207.7 million for the first quarter of 2022, while fully diluted net earnings per share were \$0.97 compared with \$0.85 in 2022, up 11.3% and 14.1%, respectively. Excluding from the first quarters of Fiscal 2023 and 2022, the amortization of intangible assets acquired in connection with the Jean Coutu Group acquisition of \$8.9 million as well as income taxes relating to these items, adjusted net earnings<sup>(1)</sup> for the first quarter of Fiscal 2023 totalled \$237.6 million compared with \$214.2 million for the corresponding quarter of 2022 and adjusted fully diluted net earnings per share<sup>(1)</sup> amounted to \$1.00 compared with \$0.88, up 10.9% and 13.6% respectively.

Net earnings for the fourth quarter of Fiscal 2022 were \$168.7 million compared with \$194.0 million for the fourth quarter of 2021, while fully diluted net earnings per share were \$0.70 compared with \$0.79 in 2021, down 13.0% and 11.4%, respectively. Excluding from the fourth quarters of Fiscal 2022 and 2021, the amortization of intangible assets acquired in connection with the Jean Coutu Group acquisition of \$9.0 million, the impairment of a loyalty program of \$60.0 million in the fourth quarter of 2022 as well as income taxes relating to these items, adjusted net earnings<sup>(1)</sup> for the fourth quarter of Fiscal 2022 totalled \$219.4 million compared with \$200.6 million for the corresponding quarter of 2021 and adjusted fully diluted net earnings per share<sup>(1)</sup> amounted to \$0.92 compared with \$0.81, up 9.4% and 13.6% respectively.

Net earnings for the third quarter of Fiscal 2022 were \$275.0 million compared with \$252.4 million for the third quarter of 2021, while fully diluted net earnings per share were \$1.14 compared with \$1.03 in 2021, up 9.0% and 10.7%, respectively. Excluding from the third quarters of Fiscal 2022 and 2021 the amortization of intangible assets acquired in connection with the Jean Coutu Group acquisition of \$11.9 million as well as income taxes relating to these items, adjusted net earnings<sup>(1)</sup> for the third quarter of Fiscal 2022 totalled \$283.8 million compared with \$261.2 million for the corresponding quarter of 2021 and adjusted fully diluted net earnings per share<sup>(1)</sup> amounted to \$1.18 compared with \$1.06, up 8.7% and 11.3% respectively.

Net earnings for the second quarter of Fiscal 2022 were \$198.1 million compared with \$188.1 million for the second quarter of 2021, while fully diluted net earnings per share were \$0.82 compared with \$0.75 in 2021, up 5.3% and 9.3%, respectively. Excluding from the second quarters of Fiscal 2022 and 2021 the amortization of intangible assets acquired in connection with the Jean Coutu Group acquisition of \$8.9 million as well as income taxes relating to these items, adjusted net earnings<sup>(1)</sup> for the second quarter of Fiscal 2022 totalled \$204.7 million compared with \$194.7 million for the corresponding quarter of 2021 and adjusted fully diluted net earnings per share<sup>(1)</sup> amounted to \$0.84 compared with \$0.78, up 5.1% and 7.7% respectively.

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



	2023	2022				2021		
<i>(Millions of dollars)</i>	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2
Net earnings	231.1	168.7	275.0	198.1	207.7	194.0	252.4	188.1
Impairment of a loyalty program, after taxes	—	44.1	—	—	—	—	—	—
Amortization of intangible assets acquired in connection with the Jean Coutu Group acquisition, after taxes	6.5	6.6	8.8	6.6	6.5	6.6	8.8	6.6
Adjusted net earnings <sup>(1)</sup>	237.6	219.4	283.8	204.7	214.2	200.6	261.2	194.7

	2023	2022				2021		
<i>(Dollars)</i>	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2
Fully diluted net earnings per share	0.97	0.70	1.14	0.82	0.85	0.79	1.03	0.75
Adjustments impact	0.03	0.22	0.04	0.02	0.03	0.02	0.03	0.03
Adjusted fully diluted net earnings per share <sup>(1)</sup>	1.00	0.92	1.18	0.84	0.88	0.81	1.06	0.78

## CASH POSITION

### OPERATING ACTIVITIES

In the first quarter of Fiscal 2023, operating activities generated cash inflows of \$210.2 million compared with \$177.0 million in the corresponding quarter of 2022. The variance is mainly due to higher earnings in 2023 compared to 2022.

### INVESTING ACTIVITIES

Investing activities required cash outflows of \$94.1 million for the first quarter of Fiscal 2023 compared with \$113.8 million for the corresponding quarter of 2022. This difference stemmed mainly from lower investments in tangible and intangible assets of \$12.2 million in 2023.

During the first quarter of Fiscal 2023, we and our retailers opened 2 stores and carried out major expansions and renovations of 3 stores for a net increase of 100,400 square feet or 0.5% of our food retail network.

### FINANCING ACTIVITIES

In the first quarter of 2023, financing activities required cash outflows of \$128.0 million compared with \$310.1 million in the corresponding quarter of 2022. This difference is mainly due to the increase in debt net of repayments totaling \$143.0 million in the first quarter of 2023.

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



## FINANCIAL POSITION

We do not anticipate<sup>(2)</sup> any liquidity risk and consider our financial position at the end of the first quarter of 2023 as very solid. We had an unused authorized revolving credit facility of \$435.5 million.

At the end of the first quarter of 2023, the main elements of our debt were as follows:

	Interest Rate	Maturity	Notional (Millions of dollars)
	Rates fluctuate with changes in bankers' acceptance rates		
Revolving Credit Facility		September 3, 2026	164.5
Series J Notes	1.92% fixed nominal rate	December 2, 2024	300.0
Series G Notes	3.39% fixed nominal rate	December 6, 2027	450.0
Series B Notes	5.97% fixed nominal rate	October 15, 2035	400.0
Series D Notes	5.03% fixed nominal rate	December 1, 2044	300.0
Series H Notes	4.27% fixed nominal rate	December 4, 2047	450.0
Series I Notes	3.41% fixed nominal rate	February 28, 2050	400.0

On November 30, 2021, the Corporation issued through a private placement Series J unsecured senior notes in the aggregate principal amount of \$300.0 million, bearing interest at a fixed nominal rate of 1.92%, maturing on December 2, 2024. In conjunction with this offering, Metro entered into a \$300.0 million interest rate swap effectively locking in a floating rate of interest of 11 basis points (0.11%) over the 3-month bankers' acceptance rate (CDOR) over the life of the Series J Notes. As at December 17, 2022, the balance of the Series J unsecured senior notes was \$287.3 million, reflecting a decrease in fair value adjustments relating to interest rate swaps designated as fair value hedges of \$12.7 million.

On December 1, 2021, the Corporation redeemed all of the Series C notes, bearing interest at a fixed nominal rate of 3.20%, in the amount of \$300.0 million that matured on the same day.

On November 14, 2022, the Corporation entered into a bond forward contract designated as cash flow hedge on a component of a highly probable future debt issuance in the amount of \$250.0 million that effectively locked-in a 10-year fixed interest rate of 2.996%.

As at December 17, 2022, the revolving credit facility included loans of \$100.0 million (US \$74.0 million) (nil as at September 24, 2022) and we entered into cross currency interest rate swaps to hedge against the effect of interest rate fluctuations on our USD borrowings.

## CAPITAL STOCK, STOCK OPTIONS AND PERFORMANCE SHARE UNITS

	As at December 17, 2022	As at September 24, 2022
Number of Common Shares outstanding ( <i>Thousands</i> )	235,142	236,594
Stock options:		
Number outstanding ( <i>Thousands</i> )	2,346	2,092
Exercise prices ( <i>Dollars</i> )	40.23 to 77.75	40.23 to 62.82
Weighted average exercise price ( <i>Dollars</i> )	55.88	51.47
Performance share units:		
Number outstanding ( <i>Thousands</i> )	555	557

## NORMAL COURSE ISSUER BID PROGRAM

Under the current normal course issuer bid program, the Corporation may repurchase up to 7,000,000 of its Common Shares between November 25, 2022 and November 24, 2023. Between November 25, 2022 and January 13, 2023, the Corporation has repurchased 696,000 Common Shares at an average price of \$74.94, for a total consideration of \$52.2 million.

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"





## DIVIDENDS

On January 23, 2023, the Board of Directors declared a quarterly dividend of \$0.3025 per share, an increase of 10.0% versus last year quarterly dividend.

## SHARE TRADING

The value of METRO shares remained in the \$67.09 to \$78.90 range over first quarter of Fiscal 2023. During this period, a total of 26.8 million shares were traded on the Toronto Stock Exchange. The closing price on January 13, 2023 was \$74.06 compared with \$69.84 at the end of Fiscal 2022.

## FORWARD-LOOKING INFORMATION

We have used, throughout this report, different statements that could, within the context of regulations issued by the Canadian Securities Administrators, be construed as being forward-looking information. In general, any statement contained herein that does not constitute a historical fact may be deemed a forward-looking statement. Expressions such as "anticipate", "continue" and other similar expressions are generally indicative of forward-looking statements. The forward-looking statements contained herein are based upon certain assumptions regarding the Canadian food and pharmaceutical industries, the general economy, our annual budget, as well as our 2023 action plan.

These forward-looking statements do not provide any guarantees as to the future performance of the Corporation and are subject to potential risks, known and unknown, as well as uncertainties that could cause the outcome to differ significantly. Risk factors that could cause actual results or events to differ materially from our expectations as expressed in, or implied by, our forward-looking statements are described and discussed under the "Risk Management" section in our Annual Report 2022.

We believe these statements to be reasonable and pertinent as at the date of publication of this report and represent our expectations. The Corporation does not intend to update any forward-looking statement contained herein, except as required by applicable law.

## NON-GAAP AND OTHER FINANCIAL MEASUREMENTS

In addition to the International Financial Reporting Standards (IFRS) measurements provided, we have included certain non-GAAP and other financial measurements. These measurements are presented for information purposes only. They do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measurements presented by other public companies.

National Instrument 52-112 Non-GAAP and Other Financial Measures Disclosure sets out specific disclosure requirements for non-GAAP financial measures, non-GAAP ratios, and other financial measures, which are capital management measures, supplementary financial measures, and total of segments measures, as defined in the Instrument (together the "specified financial measures").

The specified financial measures we disclose in our documents made available to the public are presented by measurement categories below.

### NON-GAAP FINANCIAL MEASURES

**Adjusted net earnings** is a non-GAAP financial measurement that with respect to its composition is adjusted to exclude an amount that is included in, or include an amount that is excluded from, the composition of the most directly comparable financial measure disclosed in our consolidated financial statements.

For measurements depicting financial performance, we believe that presenting earnings adjusted for these items, which are not necessarily reflective of the Corporation's performance, leaves readers of financial statements better informed thus enabling them to better perform trend analysis, evaluate the Corporation's financial performance and assess its future outlook. Adjusting for these items does not imply that they are non-recurring.

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



## NON-GAAP RATIOS

**Adjusted fully diluted net earnings per share** is a non-GAAP ratio by where a non-GAAP financial measure is used as one or more of its components.

We believe that presenting this ratio, in which a non-GAAP financial measurements is used as one or more of its components, leaves readers of financial statements better informed as to the current period and corresponding prior year's period's performance, thus enabling them to better perform trend analysis, evaluate the Corporation's financial performance and assess its future outlook. Adjusting for these items does not imply that they are non-recurring.

## SUPPLEMENTARY FINANCIAL MEASURES

The supplementary financial measures listed below are, or are intended to be, disclosed on a periodic basis to depict the historical or expected future financial performance, financial position or cash flow of the Corporation.

**Food same-store sales and pharmacy same-store sales (including total, front-store and prescription drugs)** are defined as comparable retail sales of stores with more than 52 consecutive weeks of operations, including relocated, expanded and renovated locations.

**Online food sales** are the sum of sales made from all our online channels.

**Gross margin** ratio is calculated by dividing gross profit by sales.

## OUTLOOK<sup>(2)</sup>

As we begin our second quarter, market challenges and inflationary pressures persist, and our focus remains on delivering value to our customers while executing on our strategic priorities. In a very competitive market environment, we are well positioned to meet our customers' high expectations and continue to create long-term value for our shareholders.

Montréal, January 24, 2023

<sup>(1)</sup> See table in section "Operating Results" and section on "Non-GAAP and Other Financial Measurements"

<sup>(2)</sup> See section on "Forward-looking Information"



Interim Condensed Consolidated Financial Statements

**METRO INC.**

December 17, 2022

**Table of contents**

	<b>Page</b>
Consolidated statements of income .....	13
Consolidated statements of comprehensive income .....	14
Consolidated statements of financial position .....	15
Consolidated statements of changes in equity .....	16
Consolidated statements of cash flows .....	17
Notes to interim condensed consolidated financial statements .....	18
1- Statement presentation .....	18
2- Income taxes .....	18
3- Net earnings per share .....	18
4- Debt .....	19
5- Capital stock .....	19
6- Financial instruments .....	21
7- Changes in defined benefit plans .....	21
8- Comparative figures .....	21
9- Approval of financial statements .....	22



## Consolidated statements of income

Periods ended December 17, 2022 and December 18, 2021

(Unaudited) (Millions of dollars, except for net earnings per share)

	12 weeks	
	Fiscal Year	
	2023	2022
<b>Sales</b>	<b>4,670.9</b>	4,316.6
Cost of sales	(3,755.1)	(3,455.7)
<b>Gross profit</b>	<b>915.8</b>	860.9
Operating expenses	(458.2)	(439.8)
Gain on disposal of assets	4.4	3.0
<b>Operating income before depreciation and amortization</b>	<b>462.0</b>	424.1
Depreciation and amortization	(120.1)	(112.5)
Net financial costs	(27.1)	(28.7)
<b>Earnings before income taxes</b>	<b>314.8</b>	282.9
Income taxes (note 2)	(83.7)	(75.2)
<b>Net earnings</b>	<b>231.1</b>	207.7
Attributable to:		
Equity holders of the parent	229.8	206.7
Non-controlling interest	1.3	1.0
	<b>231.1</b>	207.7
<b>Net earnings per share (Dollars) (note 3)</b>		
Basic	0.97	0.85
Fully diluted	0.97	0.85

See accompanying notes



## Consolidated statements of comprehensive income

Periods ended December 17, 2022 and December 18, 2021

(Unaudited) (Millions of dollars)

	12 weeks Fiscal Year	
	2023	2022
Net earnings	231.1	207.7
Other comprehensive income		
Items that will not be reclassified to net earnings		
Changes in defined benefit plans		
Actuarial gains (note 7)	57.0	11.9
Asset ceiling effect	(24.3)	—
Minimum funding requirement	—	1.0
Corresponding income taxes	(8.7)	(3.4)
	24.0	9.5
Items that will be reclassified later to net earnings		
Change in fair value of derivatives designated as cash flow hedges	(5.6)	—
Corresponding income taxes	1.5	—
	(4.1)	—
	19.9	9.5
Comprehensive income	251.0	217.2
Attributable to:		
Equity holders of the parent	249.7	216.2
Non-controlling interest	1.3	1.0
	251.0	217.2

See accompanying notes



## Consolidated statements of financial position

(Unaudited) (Millions of dollars)

	As at December 17, 2022	As at September 24, 2022
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	1.5	13.4
Accounts receivable	768.3	680.3
Accounts receivable on subleases	93.9	94.8
Inventories	1,496.6	1,331.1
Prepaid expenses	51.6	54.1
Current taxes	10.7	9.6
	<b>2,422.6</b>	<b>2,183.3</b>
<b>Non-current assets</b>		
Fixed assets	3,503.0	3,457.7
Investment properties	13.3	14.5
Right-of-use assets	975.9	995.1
Intangible assets	2,738.1	2,739.0
Goodwill	3,305.7	3,301.2
Deferred taxes	44.7	44.8
Defined benefit assets	155.0	127.9
Accounts receivable on subleases	459.8	478.3
Other assets	57.7	59.5
	<b>13,675.8</b>	<b>13,401.3</b>
<b>LIABILITIES AND EQUITY</b>		
<b>Current liabilities</b>		
Bank loans	20.1	0.1
Accounts payable	1,616.1	1,575.3
Deferred revenues	49.6	38.5
Current taxes	47.4	43.6
Provisions	4.7	0.5
Current portion of debt (note 4)	17.7	18.2
Current portion of lease liabilities	273.5	276.3
	<b>2,029.1</b>	<b>1,952.5</b>
<b>Non-current liabilities</b>		
Debt (note 4)	2,472.4	2,324.5
Lease liabilities	1,459.1	1,502.7
Defined benefit liabilities	29.8	30.0
Provisions	12.7	12.8
Deferred taxes	953.5	942.2
Other liabilities	17.0	18.2
	<b>6,973.6</b>	<b>6,782.9</b>
<b>Equity</b>		
Attributable to equity holders of the parent	6,687.4	6,604.5
Attributable to non-controlling interest	14.8	13.9
	<b>6,702.2</b>	<b>6,618.4</b>
	<b>13,675.8</b>	<b>13,401.3</b>

See accompanying notes



**Consolidated statements of changes in equity**  
**Periods ended December 17, 2022 and December 18, 2021**  
*(Unaudited) (Millions of dollars)*

	Attributable to the equity holders of the parent						Non-controlling interest	Total equity
	Capital stock <i>(note 5)</i>	Treasury shares <i>(note 5)</i>	Contributed surplus	Retained earnings	Accumulated other comprehensive income	Total		
Balance as at September 24, 2022	<b>1,649.3</b>	<b>(16.2)</b>	<b>23.3</b>	<b>4,947.2</b>	<b>0.9</b>	<b>6,604.5</b>	<b>13.9</b>	<b>6,618.4</b>
Net earnings	—	—	—	<b>229.8</b>	—	<b>229.8</b>	<b>1.3</b>	<b>231.1</b>
Other comprehensive income	—	—	—	<b>24.0</b>	<b>(4.1)</b>	<b>19.9</b>	—	<b>19.9</b>
Comprehensive income	—	—	—	<b>253.8</b>	<b>(4.1)</b>	<b>249.7</b>	<b>1.3</b>	<b>251.0</b>
Stock options exercised	<b>4.6</b>	—	<b>(0.5)</b>	—	—	<b>4.1</b>	—	<b>4.1</b>
Shares redeemed	<b>(10.8)</b>	—	—	—	—	<b>(10.8)</b>	—	<b>(10.8)</b>
Share redemption premium	—	—	—	<b>(97.9)</b>	—	<b>(97.9)</b>	—	<b>(97.9)</b>
Share-based compensation cost	—	—	<b>2.6</b>	—	—	<b>2.6</b>	—	<b>2.6</b>
Dividends	—	—	—	<b>(64.8)</b>	—	<b>(64.8)</b>	<b>(0.2)</b>	<b>(65.0)</b>
Buyout of minority interests	—	—	—	—	—	—	<b>(0.2)</b>	<b>(0.2)</b>
	<b>(6.2)</b>	—	<b>2.1</b>	<b>(162.7)</b>	—	<b>(166.8)</b>	<b>(0.4)</b>	<b>(167.2)</b>
Balance as at December 17, 2022	<b>1,643.1</b>	<b>(16.2)</b>	<b>25.4</b>	<b>5,038.3</b>	<b>(3.2)</b>	<b>6,687.4</b>	<b>14.8</b>	<b>6,702.2</b>

	Attributable to the equity holders of the parent						Non-controlling interest	Total equity
	Capital stock	Treasury shares	Contributed surplus	Retained earnings	Accumulated other comprehensive income	Total		
Balance as at September 25, 2021	1,674.3	(20.5)	24.2	4,721.9	—	6,399.9	12.9	6,412.8
Net earnings	—	—	—	206.7	—	206.7	1.0	207.7
Other comprehensive income	—	—	—	9.5	—	9.5	—	9.5
Comprehensive income	—	—	—	216.2	—	216.2	1.0	217.2
Stock options exercised	0.7	—	(0.1)	—	—	0.6	—	0.6
Shares redeemed	(14.1)	—	—	—	—	(14.1)	—	(14.1)
Share redemption premium	—	—	—	(114.0)	—	(114.0)	—	(114.0)
Share-based compensation cost	—	—	2.3	—	—	2.3	—	2.3
Dividends	—	—	—	(60.6)	—	(60.6)	—	(60.6)
	(13.4)	—	2.2	(174.6)	—	(185.8)	—	(185.8)
Balance as at December 18, 2021	1,660.9	(20.5)	26.4	4,763.5	—	6,430.3	13.9	6,444.2

See accompanying notes





## Consolidated statements of cash flows

Periods ended December 17, 2022 and December 18, 2021

(Unaudited) (Millions of dollars)

	12 weeks Fiscal Year	
	2023	2022
<b>Operating activities</b>		
Earnings before income taxes	314.8	282.9
Non-cash items		
Depreciation and amortization	120.1	112.5
Gain on disposal of assets	(4.4)	(3.0)
Share-based compensation cost	2.6	2.3
Difference between amounts paid for employee benefits and current period cost	6.1	3.9
Net financial costs	27.1	28.7
	466.3	427.3
Net change in non-cash working capital items	(179.3)	(182.1)
Income taxes paid	(76.8)	(68.2)
	210.2	177.0
<b>Investing activities</b>		
Buyout of minority interests	(0.2)	—
Net change in other assets	2.9	0.7
Additions to fixed assets and investment properties	(107.9)	(113.8)
Disposal of fixed assets and investment properties	5.6	0.2
Additions to intangible assets	(21.4)	(27.7)
Payments received from subleases	23.4	23.1
Interest received from subleases	3.5	3.7
	(94.1)	(113.8)
<b>Financing activities</b>		
Net change in bank loans	20.0	2.9
Shares issued	4.1	0.6
Shares redeemed	(108.7)	(128.1)
Increase in debt	145.4	307.8
Repayment of debt	(2.4)	(307.3)
Interest paid on debt	(43.5)	(46.7)
Payment of lease liabilities (principal)	(68.0)	(67.6)
Payment of lease liabilities (interest)	(11.1)	(11.5)
Net change in other liabilities	1.0	0.4
Dividends	(64.8)	(60.6)
	(128.0)	(310.1)
<b>Net change in cash and cash equivalents</b>	<b>(11.9)</b>	<b>(246.9)</b>
Cash and cash equivalents — beginning of period	13.4	445.8
Cash and cash equivalents — end of period	1.5	198.9

see accompanying notes



## Notes to interim condensed consolidated financial statements

Periods ended December 17, 2022 and December 18, 2021

(Unaudited) (Millions of dollars, unless otherwise indicated)

### 1. STATEMENT PRESENTATION

METRO INC. (the Corporation), is incorporated under the laws of Québec. The Corporation is one of Canada's leading food and pharmacy retailers and distributors. It operates a network of supermarkets, discount stores and drugstores. Its head office is located at 11011 Maurice-Duplessis Blvd., Montréal, Québec, Canada, H1C 1V6. Its business segments, food operations and pharmaceutical operations, are combined into a single reportable operating segment due to the similar nature of their operations.

The unaudited interim condensed consolidated financial statements for the 12-week period ended December 17, 2022 have been prepared by management in accordance with IAS 34 *Interim Financial Reporting* and using the same accounting policies and methods of computation as those used in preparing the audited annual consolidated financial statements for the year ended September 24, 2022. They should be read in conjunction with the audited annual consolidated financial statements and accompanying notes which were presented in the Corporation's 2022 Annual Report.

### 2. INCOME TAXES

The effective income tax rates were as follows:

(Percentage)	12 weeks	
	Fiscal Year	
	2023	2022
Combined statutory income tax rate	26.5	26.5
Changes		
Other	0.1	0.1
	26.6	26.6

### 3. NET EARNINGS PER SHARE

Basic net earnings per share and fully diluted net earnings per share were calculated using the following number of shares:

(Millions)	12 weeks	
	Fiscal Year	
	2023	2022
Weighted average number of shares outstanding – Basic	235.4	241.8
Dilutive effect under:		
Stock option plan	0.6	0.5
Performance share unit plan	0.3	0.4
Weighted average number of shares outstanding – Fully diluted	236.3	242.7



## Notes to interim condensed consolidated financial statements

Periods ended December 17, 2022 and December 18, 2021

(Unaudited) (Millions of dollars, unless otherwise indicated)

### 4. DEBT

On November 30, 2021, the Corporation issued through a private placement Series J unsecured senior notes in the aggregate principal amount of \$300.0, bearing interest at a fixed nominal rate of 1.92%, maturing on December 2, 2024. In conjunction with this offering, Metro entered into a \$300.0 interest rate swap effectively locking in a floating rate of interest of 11 basis points (0.11%) over the 3-month bankers' acceptance rate (CDOR) over the life of the Series J Notes. As at December 17, 2022, the balance of the Series J unsecured senior notes was \$287.3, reflecting a decrease in fair value adjustments relating to interest rate swaps designated as fair value hedges of \$12.7.

On December 1, 2021, the Corporation redeemed all of the Series C notes, bearing interest at a fixed nominal rate of 3.20%, in the amount of \$300.0 that matured on the same day.

On November 14, 2022, the Corporation entered into a bond forward contract designated as cash flow hedge on a component of a highly probable future debt issuance in the amount of \$250.0 that effectively locked-in a 10-year fixed interest rate of 2.996%.

As at December 17, 2022, the revolving credit facility included loans of \$100.0 (US \$74.0) (nil as at September 24, 2022) and we entered into cross currency interest rate swaps to hedge against the effect of interest rate fluctuations on our USD borrowings.

### 5. CAPITAL STOCK

#### COMMON SHARES ISSUED

The Common Shares issued and the changes during the 12-week period ended December 17, 2022 were summarized as follows:

	Number (Thousands)	
Balance as at September 25, 2021	243,391	1,674.3
Shares redeemed for cash, excluding premium of \$421.5	(7,000)	(48.5)
Stock options exercised	538	23.5
Balance as at September 24, 2022	<b>236,929</b>	<b>1,649.3</b>
Shares redeemed for cash, excluding premium of \$97.9	<b>(1,550)</b>	<b>(10.8)</b>
Stock options exercised	<b>98</b>	<b>4.6</b>
Balance as at December 17, 2022	<b>235,477</b>	<b>1,643.1</b>

#### TREASURY SHARES

The treasury shares changes during the 12-week period ended December 17, 2022 are summarized as follows:

	Number (Thousands)	
Balance as at September 25, 2021	442	(20.5)
Release	(107)	4.3
Balance as at September 24, 2022 and December 17, 2022	<b>335</b>	<b>(16.2)</b>

Treasury shares are held in trust for the PSU plan. They will be released into circulation when the PSUs settle. The trust, considered a structured entity, is consolidated in the Corporation's financial statements.



## Notes to interim condensed consolidated financial statements

Periods ended December 17, 2022 and December 18, 2021

(Unaudited) (Millions of dollars, unless otherwise indicated)

Excluding treasury shares from the Common Shares issued, the Corporation had 235,142,000 outstanding Common Shares issued as at December 17, 2022 (236,594,000 as at September 24, 2022).

### STOCK OPTION PLAN

The outstanding options and the changes during the 12-week period ended December 17, 2022 were summarized as follows:

	Number (Thousands)	Weighted average exercise price (Dollars)
Balance as at September 25, 2021	2,318	46.69
Granted	431	62.82
Exercised	(538)	38.98
Cancelled	(119)	55.79
Balance as at September 24, 2022	<b>2,092</b>	<b>51.47</b>
Granted	<b>353</b>	<b>77.75</b>
Exercised	<b>(98)</b>	<b>41.08</b>
Cancelled	<b>(1)</b>	<b>54.58</b>
Balance as at December 17, 2022	<b>2,346</b>	<b>55.88</b>

The exercise prices of the outstanding options ranged from \$40.23 to \$77.75 as at December 17, 2022 with expiration dates up to 2029. Of these options, 591,472 could be exercised at a weighted average exercise price of \$45.41.

The compensation expense for these options amounted to \$0.6 for the 12-week period ended December 17, 2022 (\$0.5 in 2022).

### PERFORMANCE SHARE UNIT PLAN

PSUs outstanding and changes during the 12-week period ended December 17, 2022 are summarized as follows:

	Number (Thousands)
Balance as at September 25, 2021	615
Granted	200
Exercised	(162)
Cancelled	(96)
Balance as at September 24, 2022	<b>557</b>
Cancelled	<b>(2)</b>
Balance as at December 17, 2022	<b>555</b>

The compensation expense for the PSU plan amounted to \$2.0 for the 12-week period ended December 17, 2022 (\$1.8 in 2022).



## Notes to interim condensed consolidated financial statements

Periods ended December 17, 2022 and December 18, 2021

(Unaudited) (Millions of dollars, unless otherwise indicated)

### 6. FINANCIAL INSTRUMENTS

The book and fair values of financial instruments, other than those with carrying amounts which were a reasonable approximation of their fair values, were as follows:

	As at December 17, 2022		As at September 24, 2022	
	Book value	Fair value	Book value	Fair value
<b>Other assets</b>				
Assets measured at amortized cost				
Loans to certain customers	45.9	45.9	49.3	49.3
<b>Debt</b>				
Liabilities measured at amortized cost				
Revolving Credit Facility	164.5	164.5	20.9	20.9
Series J Notes (note 4)	287.3	287.3	285.1	285.1
Series G Notes	450.0	430.3	450.0	418.8
Series B Notes	400.0	434.5	400.0	424.5
Series D Notes	300.0	302.1	300.0	288.6
Series H Notes	450.0	404.8	450.0	384.7
Series I Notes	400.0	309.3	400.0	292.8
Loans	50.4	50.4	49.2	49.2
	<b>2,502.2</b>	<b>2,383.2</b>	2,355.2	2,164.6

### 7. CHANGES IN DEFINED BENEFIT PLANS

The Corporation recorded, in the consolidated statements of comprehensive income, actuarial gains of \$57.0 mainly attributable to the increase in the fair value on plan assets for the 12-week period ending December 17, 2022, net of variations in the obligation. The actuarial gains of \$11.9 recorded in the consolidated statements of comprehensive income during the 12-week period ending December 18, 2021 are primarily due to the higher return on assets, net of the decrease in the discount rates from 3.33% as at September 25, 2021 to 3.28% as at December 18, 2021.

Post-employment benefits expense recorded in the consolidated statements of income during the 12-week period ending December 17, 2022 was \$17.8 (\$22.7 in 2022).

### 8. COMPARATIVE FIGURES

Cost of sales, gross profit and operating expenses have been reclassified from the Note "Additional information on the nature of earnings components". These headings are now presented separately in the consolidated statements of income. Gains on the disposal of assets totaling \$3.0 during the first quarter of 2022 have also been reclassified from operating expenses to gain on disposal of assets in the consolidated statements of income.



## **Notes to interim condensed consolidated financial statements**

**Periods ended December 17, 2022 and December 18, 2021**

*(Unaudited) (Millions of dollars, unless otherwise indicated)*

### **9. APPROVAL OF FINANCIAL STATEMENTS**

The interim condensed consolidated financial statements for the 12-week period ended December 17, 2022 (including comparative figures) were approved for issue by the Board of Directors on January 23, 2023.

#### **INFORMATION**

METRO INC.'s Investor Relations Department

Telephone: (514) 643-1000

METRO INC.'s corporate information and press releases are available on our website: [www.corpo.metro.ca](http://www.corpo.metro.ca)

***metro***